ERBB2/HER2 (HER2) amplification occurs in approximately 20% of breast cancers, leading to overexpression of the HER2 protein on the cell surface and aberrant pro-tumorigenic signaling through MAPK and PI3K pathways [1–3]. The gene discussed is ERBB2; the disease is breast cancer.